MOVVA SNEHALATHA
Senior Scientist – Formulation R&D
Innovation Plaza,
Dr. Reddy’s Laboratories Ltd
Bachupally, Qutubullapur, RR Dist – 500072
Telangana, India
Phone: +91-9000104153
Email: snehalatham@drreddys.com, snehalv3@gmail.com
Born: 31st August 1977, AndhraPradesh (India)
PERSONAL PROFILE
I am a hard working, self motivated individual having good technical and communication skills with a
keen interest to reach heights in research and development. I am an efficient team player, to
coordinate and work with different functions.
AREA OF INTEREST

Product ideation, pipeline evaluation and product selection with focus on strategy creation
 Dosage form design and development (solid orals, colloidal drug delivery systems)
EDUCATION
Ph.D. (Pharmaceutics) 2006
Pharmacy Group, Birla Institute of Technology and Science (BITS), Pilani, Rajasthan, India
Title: Studies on the Preparation, Characterization and Pharmacokinetics of Etoposide Loaded
Nanoparicles
M. Pharm. (Pharmaceutics) 2000
Department of Pharmaceutics, Institute of Technology, Banaras Hindu University (BHU), Varanasi,
India.
Title: Preparation and Characterization of Calcium alginate and Calcium pectinate Beads of Ketoprofen
B. Pharm.1999
KVSR Siddhartha College of Pharmaceutical Sciences, Nagarjuna University, Vijayawada, India.
INDUSTRIAL EXPERIENCE
Dr. Reddy’s Laboratories Ltd. [Aug, 2006 to Till date]
working as Senior Scientist- Formulation Research and Development
Responsibilities in the current role are

Contributing in building up the product pipline, strengthening through a thorough technical
evaluation of drug molecules.

Presented detailed evaluation note converging the idea from various CFTs and reporting the
same at Pre-apex and Apex stages

Collaboration and connecting with API portfolio team providing visibility on formulation.
1 of 3

Synchronizing the product portifolio bridging between API and formulation pipelines

Supporting HPT with a full kit development comprising all the highlights and low lights of the
product

Deeper insights to HPTs through deformulation approaches and anticipating the most probable
reference composition

Development of non-infrigining formualtion strategies circumventing the IP block, help HPT
avail freedom to operate and IP fencing to reduce compeitition.

Development of strategies backed with sound visibility of QbD and scalbility with risk mitigation
approaches.

Experimentation to crack the critical aspects of product. Ex: alternate polymorph/salt,
preformulation, formulation IP, process feasibility.
Previous assignments:

Development of formulations with bioequivalent profiles for the regulated markets – first to file
and complex generics products

QbD based formulation development.

Experimenting novel methodologies/approaches from development, execution to filing to
achieve first-to-file.

Product selection process, strategy creation during selection and introduction for
development. Involved in the review process of products during pipeline selection.

Intellectual value creation for the organization through generation of patents by working
closely with the IP team.

Non-infringing and patentable new polymorphs evaluation for existing and new drugs and
stabilization of Polymorphs in the formulations.

Experience on various dosage forms like tablets, capsules, pellets etc including immediate,
delayed and modified release technologies.
ACHIEVEMENTS - INDUSTRY

Successfully filed first - to- file products within few months of reference product launch

First time in DRL, developed and executed sublingual dosage form within the shortest duration

Created intellectual property value for organization through many patent filings

Received award for Best complex product development and execution

Received award for best cross functional initiative – Creating IP position and valued for the
company

Won chairman’s excellence award for “Best Innovative Team” for the year 2010 as a part of
team for developing difficult dosage forms
PATENT APPILCATIONS

Modified-release formulations of calcium receptor-active compounds WO 2008/064202

Solifenacin compositions WO 2008/128028

Trospium pharmaceutical formulations WO 2009/052353
2 of 3

Sustained release Donepezil formulations WO 2011/069076

Sustained release Zolpidem formulations 20130143912A1
 Inventions filed as provisional applications - 5
ACHIEVEMENTS - ACADEMICS

Scored 75.5% in B. Pharm. with Distinction

Secured 97.98 percentile in GATE-1999 (ranked 50 in all India ranking) conducted by IIT
Mumbai (in Pharmaceutical Sciences stream)

Awarded CSIR senior research fellowship in the year 2003

Awarded International Travel Grant by CSIR, for presenting research paper and attending 32nd
Annual Meeting and Exposition of Controlled Release Society held in Miami Beach, USA,
between 18th to 22nd June, 2005.

Editorial member for Journal of bioequivalence and bioavailability – OMICS publications
 Reviewer for many articles – different renowned journals.
PUBLICATIONS

M. Snehalatha, Nontraditional designs for proving bioequivalence. Journal of Bioequivalence
and bioavailability, August 2011.

M. Snehalatha, K. Venugopal and R.N. Saha, Etoposide loaded PLGA and PCL nanoparticles I:
Preparation and effect of formulation variables. Drug Delivery, 2008, Volume 15 (5): 267-275.

M. Snehalatha, K. Venugopal and R.N. Saha, Etoposide loaded PLGA and PCL nanoparticles II:
Preparation biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug
Delivery, 2008, Volume 15 (5): 277-287.

M. Snehalatha, B. Girish, K. Venugopal and R.N. Saha, "Validated, reverse phase high
performance liquid chromatographic method for the estimation of etoposide in bulk and
formulations", October-December 2007, Indian J. Pharm. Educ. Res, Volume 41, Issue 4.

M. Snehalatha and R. N. Saha, “New, sensitive and validated spectrofluorimetric method for
the estimation of Etoposide in bulk and pharmaceutical formulations”, 2006, Pharmazie,
Volume 61, 664-666.

K. Venugopal, M. Snehalatha, B. Girish and R.N. Saha, "Development and Validation of IonPairing RP-HPLC Method for the Estimation of Gatifloxacin in Bulk and Formulations", April
2007, Journal of Chromatographic Sciences, Volume 45, Issue 4, 166-172.

K. Venugopal, M. Snehalatha and R.N. Saha, "New, rapid and Sensitive Spectrofluorimetric
Method for the Estimation of Gatifloxacin in Bulk and Formulations", November-December
2006, Indian Journal of Pharmaceutical Sciences, Volume 68, Issue 6, 726-730.

Saha, Ranendra N; Sekar, Vasanthakumar; Bende, Girish; M. Snehalatha, “Nanoparticulate drug
delivery systems for cancer chemotherapy”, October 2010, Mol Membr Biol, Volume 27, Issue
7, 215-231.
PAPER PRESENTATIONS
 Around 10 papers presented in several national and international seminars/workshops.
3 of 3